Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03164512 · ClinicalTrials.gov registry record · Phase 1
The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol
A Phase 1 study of Cannabidiol Pharmacokinetics, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT03164512: Completed Phase 1 study of Cannabidiol Pharmacokinetics, sponsored by Johns Hopkins University.
NCT03164512 is a Phase 1 study of Cannabidiol Pharmacokinetics that has completed, run by Johns Hopkins University. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03164512, a Phase 1 study of Cannabidiol Pharmacokinetics, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the pharmacokinetics and pharmacodynamics of cannabidiol administered via inhalation and oral ingestion.
Primary Outcome
THC-COOH in Urine
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oral or vaporized cannabidiol
Study Locations (1)
Maryland
- Johns Hopkins Behavioral Pharmacology Research Unit - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2020-01-22 |
| Phase | Phase 1 |
What the finished NCT03164512 record still lists
NCT03164512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Cannabidiol Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03164512 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03164512 about?
NCT03164512 is a clinical study titled "The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol". This study will evaluate the pharmacokinetics and pharmacodynamics of cannabidiol administered via inhalation and oral ingestion.
What is the current status of trial NCT03164512?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2018-06-01. Estimated completion is 2020-01-22.
What conditions does trial NCT03164512 study?
This clinical trial studies the following conditions: Cannabidiol Pharmacokinetics.
What interventions are being tested in trial NCT03164512?
The interventions under investigation include: Placebo (DRUG), Oral or vaporized cannabidiol (DRUG).
Who is sponsoring clinical trial NCT03164512?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03164512 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03164512's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI